Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

TQG 202

Next Previous
Search
Drug Profile

TQG 202

Alternative Names: Factor VIII biosimilar - Alphamab; KN 008

Latest Information Update: 13 Mar 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Alphamab
  • Developer Chia Tai Tianqing Pharmaceutical Group
  • Class Antihaemorrhagics; Blood coagulation factors; Recombinant proteins
  • Mechanism of Action Factor VIII replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Haemophilia A

Most Recent Events

  • 07 Mar 2024 Chia Tai Tianqing Pharmaceutical Group plans a phase III trial in Hemophilia A (Treatment-experienced) in China (Parenteral) in April 2024 (NCT06297655)
  • 06 Nov 2022 Adverse events and pharmacokinetics data from a phase III in haemophilia A released by Chia Tai Tianqing Pharmaceutical
  • 06 Nov 2022 Chia Tai Tianqing Pharmaceutical completes a phase-III clinical trial in Haemophilia A (Treatment-experienced) in China (IV) as of November 2022 (NCT04061109)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top